Skip to main content
Equibles
PPCB logo

PPCB · Propanc Biopharma, Inc. · Metrics

Track PPCB — free

Use PPCB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PPCB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.99 +0.07 (+3.65%)
Rebalance outlook locked
Going-concern doubt — flagged Sep 25, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These matters raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-K filed Sep 25, 2026
Market Cap
$1.22M
Shares
633,112
Volume · Nov 12 21.9K Avg daily vol (14 sessions) 35.67K

PPCB metrics

42 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.92
Market cap
$1.22M

Price action

23 metrics
Price change (1W)
+2.8%
Price change (30D)
-19.7%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
—
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
633,112

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.1
reciprocal yield 807.1%
FCF yield
-488.2%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,619.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$18.19M
Net income (TTM)
−$18.86M
Trailing 12 months
Diluted EPS (TTM)
$-176.20
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$28.40

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
-99.6%
Shares change YoY
+418.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-200.6%
Return on assets
-147.6%
Debt / equity
0.0
Current ratio
2.5
EBITDA (TTM)
—
Free cash flow (TTM)
−$5.69M
Quick ratio
2.5
Interest coverage
-42.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$426,477
Latest balance sheet
Cash & equivalents
$93,241
Total assets
$12.78M
Total debt
$55,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$5.68M
Capital expenditures (TTM)
$4,933
R&D (TTM)
$625,477
SG&A (TTM)
—
Stock compensation (TTM)
$8.50M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
4
13F filer change QoQ
-2
Institutional ownership
0.8%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
0.5%
Active holders' share change QoQ
+158.9%
Holder tenure
1.5
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
3.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
56 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1517681 CUSIP 74346N800 13F (30d) 5 filings 5 filers Visit website Investor relations